RecruitingNot ApplicableNCT06705153

The Effect of Laughter Yoga on Symptom Severity, Depression-anxiety-stress, Sleep Quality and Quality of Life in Patients with Irritable Bowel Syndrome

The Effect of Laughter Yoga in Patients with Irritable Bowel Syndrome: a Randomized Controlled Trial

Sponsor

Ataturk University

Enrollment

56 participants

Start Date

Dec 4, 2024

Study Type

INTERVENTIONAL

Conditions

Irritable Bowel Syndrome

Summary

The study will be conducted to evaluate the effect of laughter yoga on symptom severity, depression, anxiety, stress, sleep and quality of life in patients with Irritable Bowel Syndrome (IBS). The following hypotheses will be tested in this study: H1: Laughter yoga reduces symptom severity in patients with IBS. H2: Laughter yoga reduces depression, anxiety and stress in patients with IBS. H3: Laughter yoga improves sleep quality in patients with IBS. H4: Laughter yoga improves quality of life in patients with IBS.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria8

Diagnosed with IBS according to Rome IV criteria,
Scoring 75 and above on the IBS-SSS score,
DASS-42 scores of 10 and above for depression, 8 and above for anxiety, 15 and above for stress,
Over 18 years of age,
Bleeding hemorrhoids, all types of hernia, persistent cough, severe back pain, heart diseases, high blood pressure, urinary incontinence, major psychiatric diseases, pregnancy, cold/flu, no epilepsy, no surgery in the last three months, etc.
Patients with a smartphone/computer where it is possible to participate in a video call for laughter yoga,
Patients without communication problems and
Patients who agree to participate in the study will be included in the study.

Exclusion Criteria4

who do not practice laughter yoga,
who do not attend regularly,
Patients whose treatment regimen has changed and
Patients who wish to leave the study will be excluded from the study.

Interventions

OTHERlaughter yoga

Patients who come to the outpatient clinic will be met, informed about the study and written informed consent will be obtained from patients who agree to participate in the study. Patient information form will be applied, baseline measurements will be made (IBS-SSS, DAS-42, PSQI and IBS-QOL) and IBS type will be determined according to Bristol stool scale. Type 1-2 constipation, Type 6-7 diarrhea, Type 1 or Type 2 at the same time with Type 6 or Type 7 will be considered as mixed type IBS and those who do not fit any of the scales will be considered as unclassifiable IBS. A total of 8 sessions will be held with the patients in the intervention group in the form of meetings via zoom with the help of a smart cell phone/computer (2 weekly sessions). The meetings will be in 3 groups.